Acute inflammatory demyelinating polyneuropathy (AIDP) is an aggressive antibody-and T-cell-mediated variant of Guillain-Barr e Syndrome (GBS), a prominent and debilitating autoimmune disorder of the peripheral nervous system. Despite advancements in clinical management, treatment of patients with AIDP/GBS and its chronic variant CIDP remains palliative and relies on the use of non-specific immunemodulating therapies. Our laboratory has previously reported that therapeutic administration of statins safely attenuates the clinical severity of experimental autoimmune neuritis (EAN), a well-characterized animal model of AIDP/ GBS, by restricting the migration of autoreactive leukocytes across peripheral nerve microvascular endoneurial endothelial cells that form the blood-nerve barrier. Despite these advancements, the clinical application of systemically administered statins for the management of inflammatory disorders remains controversial as a result of disappointingly inconclusive phase trials. Here, poly(lactic-co-glycolic) acid (PLGA) nanoparticles were evaluated as an alternative strategy by which to locally administer statins for the management of EAN. When tested in vitro, lovastatin-encapsulating PLGA nanoparticles elicited a marked increase in RhoB mRNA content in peripheral nerve microvascular endoneurial endothelial cells, similar to cells treated with activated unencapsulated lovastatin. Unilateral peri-neural administration of lovastatin-encapsulating PLGA nanoparticles, but not empty nanoparticles, to na€ ıve Lewis rats similarly enhanced RhoB mRNA content in adjacent nerve and muscle tissue. When administered in this manner, serum levels of lovastatin were below the level of detection. Bilateral peri-neural administration of lovastatin-encapsulating PLGA nanoparticles to EAN-induced Lewis rats significantly attenuated EAN clinical severity while protecting against EAN-induced peripheral nerve morphological and functional deficits. This study provides the first proof-of-concept approach for the application of a nanoparticle-based local drug delivery platform for the management of inflammatory demyelinating diseases, including AIDP/GBS.
Acute inflammatory demyelinating polyneuropathy (AIDP) is a North American and European variant of GuillainBarr e Syndrome (GBS), a leading cause of acute flaccid paralysis in Western countries (Flachenecker 2006 ) with a reported annual stable incidence rate of 0.2-4.0 cases per 100 000 (McGrogan et al. 2009; Sejvar et al. 2011) . In the US alone, nearly 10 000 GBS cases are reported annually with an overall yearly socioeconomic burden exceeding $1.7 billion (Frenzen 2008) . Characterized clinically by acute aggressive ascending paresis, this autoimmune peripheral nerve disorder can affect individuals of all age groups (5-89 years) with a unique male : female preferential ratio~1.6 : 1 (Blum et al. 2013) . Although rarely fatal, in some affected patients life-preserving mechanical ventilation and prolonged supportive clinical care is required. Despite its prevalence and overwhelming socioeconomic impact, the pathophysiology of AIDP/GBS remains unclear. Aberrant cell-mediated autoimmune responses directed against specific constituents of peripheral nerve myelin are considered causal in AIDP (Hartung et al. 1988 . Enhanced infiltration of inflammatory cells into peripheral nerves is strongly suggestive of a Th1-cell-mediated process (Csurhes et al. 2005; Willison 2005; McCombe and Csurhes 2010) . Therapeutic strategies for the management of AIDP/GBS currently utilize nonspecific therapies that target the immune system as a whole (Lindenbaum et al. 2001) .
In general, various agents that exhibit anti-inflammatory properties (Zhang et al. 2009; Li et al. 2011; Han et al. 2014; Xiao et al. 2014) or antagonists of inflammatory mediators (Archelos et al. 1993; Bao et al. 2003; Mao et al. 2010; Yuan et al. 2014) show therapeutic potential (Hahn 1996; Gold et al. 2000) at lessening experimental disease severity, consistent with a central role of aberrant inflammation in the pathogenesis of AIDP/GBS. Strategies which selectively target and disrupt autoreactive leukocyte trafficking into affected peripheral nerves, however, represent an attractive and promising new option for improved therapeutic management of patients with AIDP/GBS. One such experimental strategy previously evaluated by our laboratory involves systemic administration of statins, a class of generally well-tolerated cholesterol lowering agents. A short-term high-dose course of statins was found to markedly restrict the transendothelial trafficking of autoreactive leukocytes into peripheral nerves of Lewis rats and safely attenuate the development and progression of experimental autoimmune neuritis (EAN), a well-established model of AIDP/ GBS (Sarkey et al. 2007) .
In vitro, we have shown that statins significantly attenuate tumor necrosis factor (TNF)-a-mediated release of the leukocyte-recruiting chemokine (C-C motif) ligand 2 from cultured peripheral nerve microvascular endoneurial endothelial cells, the barrier-forming cells that line the vessels of the peripheral nerves (Langert et al. 2013b (Langert et al. , 2014 . Moreover, statins attenuate endothelial cell adhesion molecule expression, NFjB activation, and CD40 expression (Takeuchi et al. 2000; Zapolska-Downar et al. 2004; Lin et al. 2006; Stach et al. 2012; Wu et al. 2013) . These findings are consistent with welldocumented pleiotropic effects of statins (Goldstein 2007; Kim et al. 2007; Cai et al. 2015) . Although the precise mechanisms remain to be determined, it is well-established that statins can limit the trafficking of autoreactive leukocytes across activated endothelial barriers (Greenwood et al. 2003; Ifergan et al. 2006; Maher et al. 2009 ). In vivo, statins attenuate disease severity in both EAE and EAN animal models of inflammatory autoimmune disease (Stanislaus et al. 2001 (Stanislaus et al. , 2002 Greenwood et al. 2003; Sarkey et al. 2007 ). When applied clinically either as a monotherapy or as an addon therapy to interferon-beta, however, phase trials evaluating statins (up to 80 mg daily) for the treatment of relapsingremitting or progressive multiple sclerosis (MS) or clinically isolated syndrome have been disappointingly inconclusive (Sorensen et al. 2011; Chataway et al. 2014; Pihl-Jensen et al. 2015) . There is evidence to support a beneficial effect of statins in secondary progressive MS (Pihl-Jensen et al. 2015) . Whether because of immunomodulation or neuroprotection, the potential benefit of statins for the management of autoimmune neuropathies warrants further study. Nanotechnology-based drug delivery represents a relatively new and innovative approach by which to administer therapeutic compounds exhibiting low bioavailability, high systemic toxicity, and/or poor water solubility, including statins (Wischke and Schwendeman 2008; Romana et al. 2014; Sirtori 2014) . Poly(lactic-co-glycolic) acid (PLGA) nanoparticles are ideal biodegradable candidates which efficiently encapsulate hydrophobic compounds for controlled and sustained release (Astete and Sabliov 2006; Kulkarni and Kompella 2014) . Local administration of statin-encapsulating PLGA nanoparticles accelerates healing in pre-clinical bone fracture models by increasing transcription of BMP-2 at the site of injury (Garrett et al. 2007; Ho et al. 2011) .
Here, we report that a bilateral peri-neural injection of lovastatin-encapsulating biodegradable PLGA nanoparticles protects against the clinical progression of EAN and associated peripheral nerve functional, histological, and neuropathological deficits.
Materials and methods
PLGA nanoparticle preparation and characterization Unless otherwise specified, analytical grade reagents were obtained from Sigma-Aldrich (St Louis, MO, USA). Nanoparticles were prepared using an oil-in-water single emulsion technique (McAlvin et al. 2013; McCall and Sirianni 2013) . Briefly, 100 mg of PLGA (85 : 15 or 50 : 50, viscosity 0.26-0.54; Durect Corp., Birmingham, AL, USA) was dissolved in dichloromethane (1 mL) and slowly added to ice-cold 1% (w/v) polyvinyl alcohol (10 mL) while vigorously vortexing. The resultant suspension was emulsified by probe sonication and subsequently diluted with 100 mL ice-cold polyvinyl alcohol. The organic solvent was allowed to evaporate with constant stirring for 3 h at 23°C and the resulting PLGA nanoparticles were isolated by centrifugation (25 000 g 9 20 min @ 4°C) and washed 39 with deionized water. Washed nanoparticles were resuspended in 10 mL deionized water and 50 mg sucrose was added as a lyoprotectant (Howard et al. 2012) . PLGA nanoparticles were lyophilized and stored at À80°C. Lovastatin-encapsulating PLGA nanoparticles were prepared in a similar manner by dissolving 10-50 mg lovastatin (Calbiochem/Millipore, Billerca, MA, USA) in the initial organic phase. PLGA nanoparticle size was determined by dynamic light scattering using a Malvern NanoSight NS500 analyzer (Malvern Instruments Ltd, Westborough, MA, U.S.A.).
To determine percent drug-loading and encapsulation efficiency, PLGA nanoparticles were dissolved in dimethyl sulfoxide (5 mg/mL) and encapsulated lovastatin resolved by HPLC (Hitachi LaChrom Elite, model 2200, Hitachi High-Technologies in America, Schaumburg, IL, U.S.A.) using a Beckman Coulter Ultrasphere 5 lm C18 reverse-phase column (4.6 mm 9 25 cm). An isocratic mobile phase of acetonitrile: 0.05N formic acid (70 : 30, v/v) was used to elute lovastatin from the column at a rate of 1 mL/min. Lovastatin was quantified (240 nm) using an external standard curve prepared in dimethylsulfoxide.
Static dialysis of lovastatin-encapsulating PLGA nanoparticles Lovastatin-encapsulating PLGA nanoparticles (2.5-10 mg) were suspended in 1 mL phosphate-buffered saline (pH 7.4, 37°C), placed in 5 cm 9 10 mm pre-soaked and rinsed Spectra/Por Biotech regenerated cellulose dialysis membrane tubing (Spectrum Laboratories (Rancho Dominguez, CA, U.S.A.), MWCO: 3.5-5 kDa), and the suspension dialyzed at 37°C by immersion in 50 mL phosphate-buffered saline (PBS) containing 0.05% NaN 3 with continuous gentle stirring. At timed intervals, an aliquot of the dialysate was removed and replaced with an equal volume of PBS. Lovastatin present in the dialysate was quantified by HPLC as described above, with an external standard curve prepared in PBS.
Peripheral nerve microvascular endoneurial endothelial cell culture Unless otherwise specified, cell-culture reagents were obtained from Life Technologies (Grand Island, NY, USA). An immortalized cell line of peripheral nerve microvascular endoneurial endothelial cells (PNMECs) was prepared from purified rat primary PNMECs using a replication-deficient SV40 retrovirus encoding a temperaturesensitive, non-SV40 origin-binding mutant of the large T antigen and a selectable neomycin resistance gene as previously described (Langert et al. 2013a) . Immortalized PNMEC cultures were maintained in Ham's F10 basal media supplemented with 10% fetal bovine serum (FBS), 5.6 lg/mL amphotericin B, 100 U/mL penicillin, 100 lg/mL streptomycin, 50 lg/mL ECGS (BD Biosciences, San Jose, CA, USA), and 0.4 lg/mL heparin (SigmaAldrich), under an atmosphere of 5% CO 2 /95% air.
In vitro evaluation of PLGA nanoparticle function Empty-or lovastatin-encapsulating PLGA nanoparticles were suspended in culture media and 40 lg added to confluent PNMEC cultures seeded on collagen-coated (6.0 lg/cm 2 , rat tail collagen type I; Millipore) 6-well tissue culture plates. After 24 h, total RNA was extracted from PNMEC cultures with TRIzol reagent and 5 lg was reverse transcribed using Super Script III First Strand Synthesis system (Life Technologies) as previously described (Von Zee et al. 2009 ). Rat-specific RhoA and RhoB cDNA sequences were amplified by real-time PCR on a Mini-Opticon PCR detection system using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) with the following primer pairs: RhoA: forward, 5 0 -TGAAAACTA Optimized amplification steps of 94°C 9 5 min followed by 94°C 9 15 s, annealing at 55°C 9 30 s, and elongation at 72°C 9 60 s were used. Reaction efficiencies were typically > 90%. For each sample, the specificity of the real-time reaction product was determined by melt curve analysis.
In vivo evaluation of PLGA nanoparticle function This study was conducted using protocols approved by the Edward Hines Jr. VA Hospital Institutional Animal Care and Use Committee in accordance with the principles of laboratory animal care (NIH Publication No. 86-23, 1985) . All animals were housed in pairs, allowed access to standard rat chow and water ad libitum, and maintained on a 10/14 h light/dark cycle. Na€ ıve adult male Lewis rats (initial body weight 250 g; Envigo, Indianapolis, IN, USA) were anesthetized with ketamine (100 mg/kg)-xylazine (5 mg/kg) prior to PLGA nanoparticle administration. Although AIDP/GBS develops slightly more frequently in males more than females, the use of male rats in this study was chosen based on our previously published findings (Sarkey et al. 2007 ). Empty or lovastatin-encapsulating PLGA nanoparticles were suspended in 1% sodium carboxymethylcellulose and 0.1% Tween 80 in sterile PBS at a concentration of 80 mg/mL. PLGA nanoparticles (250 lL) were administered bilaterally using a 20-gauge needle inserted posteromedial to the greater trochanter to a depth of 16 mm, pointing in a posterolateral direction. In some experiments, empty PLGA nanoparticles were injected on left side and lovastatin-encapsulating PLGA nanoparticles injected on the right side. In these studies, animals were sacrificed 7 days after PLGA nanoparticle injection, trunk blood was collected, and sciatic nerves and adjacent muscle were collected from each leg. PLGA nanoparticles administered in this manner were visible upon exposure as a localized globular deposit (dashed arrow) adjacent the nerve fiber bundle (solid arrow). RNA was extracted from sciatic nerve and adjacent muscle tissue with TRIzol reagent, and RT-PCR analysis of RhoA and RhoB mRNA content was performed as described above.
Experimental autoimmune neuritis
Five days after administering PLGA nanoparticles, rats were actively induced with EAN as previously described (Sarkey et al. 2007; Calik et al. 2015) . Rats were anesthetized with ketamine (100 mg/kg)-xylazine (5 mg/kg) and 100 lL of a freshly prepared fine-particle emulsion (1 : 1 v/v) containing 100 lg of a synthetic neuritogenic P2 peptide (53-78, Peptide Synthesis Core Facility of the Simpson Querrey Institute, Northwestern University) suspended in sterile saline and incomplete Freund's adjuvant (Sigma-Aldrich) supplemented with 5 mg/mL heat-inactivated Mycobacteria tuberculosis (strain H37Ra; Difco Laboratories, Detroit, MI, USA) was injected into the left hind footpad. Rats were scored daily for EAN by investigators blinded to group assignment. The severity of clinical signs was scored as follows: 0 = no symptoms; 1 = flaccid tail; 2 = abnormal gait; 3 = mild paraparesis; 4 = severe paraparesis; 5 = paraplegia. Intermediate clinical signs were scored in increments of 0.5.
Peripheral nerve conduction studies
Evoked compound muscle action potential (CMAP) amplitudes were recorded and sciatic nerve conduction velocities (NCV) were calculated as previously described (Sarkey et al. 2007 ). Prior to EAN induction (baseline) and again at peak of disease (Day 15-17), sciatic nerves of anesthetized rats were stimulated at the sciatic notch or at the ankle (tibial nerve) with unipolar pin electrodes using supramaximal stimuli (25 mA, 0.05-ms duration) at high frequency (1 Hz) for the direct measurement of motor nerve (M-wave) responses. Unipolar pin recording electrodes were used to record the evoked potentials from the plantar muscles of the uninjected right hind foot. Individual responses were amplified and recorded using a TECA Synergy electromyograph system. For each animal, M-wave-evoked responses elicited from distal (ankle) or proximal (sicatic notch) sites were captured as an average of 25 individual responses. Three averaged responses elicited from distal and proximal stimulation sites were recorded for each animal. Motor NCV was calculated as the distance from notch to ankle divided by the average difference in the M-wave latency (notch-ankle). A heating pad was used to maintain the body temperature of the rat at 37°C.
Histology and immunohistochemistry
Following nerve conduction studies performed at peak of disease, sciatic nerves (3-4 cm) were rapidly harvested, bisected, and immediately fixed in ice-cold 2% paraformaldehyde-2.5% glutaraldehyde phosphate-buffered solution for 24 h at 4°C or snap frozen in Tissue Tek optimum cutting temperature (O.C.T.) and chilled isopentane and stored at À80°C. For histological analysis, paraformaldehyde-fixed nerves were post-fixed in 1% osmium tetroxide, dehydrated, and embedded in Embed-812 (Electron Microscopy Sciences, Fort Washington, PA, USA). Serial transverse sections (0.5 lm) were prepared with a Reichert Ultracut S microtome (W. Nuhsbaum Inc., McHenry, IL, USA) and osmicated sections were stained with toluidine blue. Stained sections were viewed using a Leitz DMRB inverted-phase contrast microscope. Representative images were captured with a Leica Wild MPS photographic system (Leica microsystems, Buffalo Grove, IL, U.S.A.) and scored, by a blinded investigator, using a four-point scoring system for pathological changes (demyelination, axonal damage, cellular infiltration, and edema) as previously described (Sarkey et al. 2007) .
For immunohistochemical analysis of CD4 + and CD68 + infiltrates, 8 lm transverse sections of snap-frozen nerves were prepared with a cryostat and placed onto Superfrost Plus microscope slides. Sections were air dried, washed in PBS to remove OCT, and fixed in 3.7% paraformaldehyde (10 min, 23°C). Washed sections were blocked 9 1 h at 23°C in PBS containing 3% bovine serum albumin, 1% normal goat serum, and 0.3% Triton X-100 (blocking buffer). Washed sections were incubated overnight at 4°C in blocking buffer supplemented with a 1 : 100 dilution of mouse antirat CD4 (clone W3/25, purified IgG) or mouse anti-rat CD68 (clone ED1, purified IgG) primary antibody (Bio-Rad) and a 1 : 50 dilution of rabbit polyclonal CD31 primary antibody (ThermoFisher Scientific, Asheville, NC, U.S.A. 
Results
In vitro characterization of lovastatin-encapsulating PLGA nanoparticles Nanoparticles with varying lactide : glycolide ratios (50 : 50 or 85 : 15; inherent viscosity 0.26-0.54 and 0.55-0.75, respectively; Durect Corp.) were prepared without (empty particles) or with lovastatin at a theoretical drug-loading content of 6.25% (w/w) or 25.0% (w/w) and characterized by dynamic light scattering (particle size) and HPLC (drugloading efficiency). Independent of polymer composition or drug-loading efficiency, PLGA nanoparticles exhibited a particle size of 260.0 AE 14.4 nm ( Table 1) . At 6.25% (w/w), encapsulation efficiencies ranged from 87.4 AE 4.4% to 104.3 AE 4.1, depending on the polymer composition (Table 1 ). The release of encapsulated lovastatin from PLGA nanoparticles into an aqueous environment was characterized in vitro by static dialysis. Empty or lovastatin-encapsulating PLGA nanoparticles (10 mg) were dialyzed against PBS at 37°C under gentle continuous mixing. At selected timed intervals, an aliquot of the dialysate was removed and analyzed by HPLC. The dialysate contained a single compound eluting on HPLC with a retention time of 5.6 min, identified by co-migration with authentic active (open-ring) b-hydroxy acid form of lovastatin (Fig. 1a , green and black traces). By comparison, dissolving lovastatinencapsulating PLGA nanoparticles directly in dimethylsulfoxide yielded a single compound eluting on HPLC with a retention time of 8.5 min, identified by co-migration with authentic inactive pro-drug (b-lactone) of lovastatin (Fig. 1a , red and blue traces). These findings suggest that encapsulated lovastatin remains as an inactive pro-drug. Only after release does the lactone ring of lovastatin become hydrolyzed thereby activating this compound. Cumulative release was quantified over a period of 30 days using an external standard curve prepared in PBS. In all cases, within 25.1 AE 4.9 days (n = 9), release of encapsulated lovastatin was complete (Fig. 1b) . At 6.25% (w/w) or 25% (w/w), lovastatin-encapsulating nanoparticles with a 85 : 15 lactide : glycolide ratio achieved 50% release by 10.7 AE 1.1 days or 9.7 AE 0.6 days, respectively (n = 3). By comparison, nanoparticles prepared using a 50 : 50 lactide : glycolide ratio achieved 50% release by 17.3 AE 4.6 days (Fig. 1b) .
To determine the functional activity of lovastatin released from PLGA nanoparticles, semi-confluent cultures of immortalized PNMECs were incubated 9 24 h in the presence of 40 lg nanoparticles and evaluated for changes in small GTPase mRNA expression. Previous studies have shown that treating cultured cells with statins limits the availability of isoprenoid metabolic intermediates leading to a marked compensatory increase in constitutive RhoA and inducible RhoB mRNA expression (Von Zee et al. 2009 ). Treating PNMECs cultures with activated lovastatin (10 lM, 24 h) did not significantly alter constitutive levels of RhoA mRNA (Fig. 2a) . By comparison, however, a 10-to 15-fold increase in inducible RhoB mRNA content was observed in PNMEC cultures treated with activated lovastatin (10 lM, 24 h) when compared to vehicle-treated control (Fig. 2a) . PNMECs cultured in the presence of 40 lg lovastatin-encapsulating PLGA nanoparticles exhibited a robust 20-fold increase in inducible RhoB mRNA content (Fig. 2b) . Constitutive levels of RhoA mRNA, although increased in response to lovastatin-encapsulating nanoparticles, did not achieve statistical significance (Fig. 2b) . PNMECs cultures treated with empty PLGA nanoparticles (40 lg) had no effect on either RhoA or RhoB mRNA expression (Fig. 2b) . These findings suggest that encapsulating lovastatin within PLGA nanoparticles does not alter the ability of this pro-drug to become functionally active under physiologic conditions.
In vivo characterization of lovastatin-encapsulating PLGA nanoparticles To determine whether locally administered lovastatinencapsulating PLGA nanoparticles can functionally alter expression of small GTPases mRNA content in vivo, healthy male Lewis rats were injected with 20 mg (250 lL, single bolus) of empty (left leg) and 20 mg (250 lL, single bolus) of 25.0% (w/w) lovastatin-encapsulating nanoparticles (right leg). Sciatic nerves (Fig. 3a) and adjacent muscle tissue (Fig. 3b) harvested from the right lovastatin-treated leg expressed a significant 5-fold increase in inducible RhoB mRNA content as compared to tissue harvested from the left control leg ( Fig. 3a and b) . For each tissue, by comparison, lovastatin-encapsulating nanoparticles elicited a qualitatively similar increase in the constitutive expression of RhoA mRNA content compared to empty nanoparticles ( Fig. 3a and b) . These findings suggest that lovastatin-encapsulating nanoparticles act locally on adjacent tissue, rather than through systemic circulation. Consistent with this thesis, the levels of circulating lovastatin pro-drug, or active b-hydroxy acid form, present in sera from rats receiving lovastatin-encapsulating nanoparticles were below the limit of HPLC detection. In contrast, circulating levels of active lovastatin present in serum samples prepared from blood of healthy male Lewis rats 1 h after receiving oral (100 mg/kg) or intraperitoneal (10 mg/kg) lovastatin pro-drug were 385.3 AE 53.7 ng/mL (n = 6) and 937.5 AE 50.4 ng/mL (n = 3), respectively (Table 2) . To determine whether peri-neural administration of lovastatin-encapsulating PLGA nanoparticles induces localized toxicity or injury to peripheral nerves, nerve function studies were performed on healthy male Lewis rats. Prior to (baseline, day 0) and 7 days following unilateral injection of 20 mg lovastatin-encapsulating nanoparticles (25% w/w), evoked CMAP amplitudes were recorded and NCV calculated. Evoked CMAP amplitudes (Fig. 3c) and NCV (Fig. 3d) determined from the injected right legs of rats receiving lovastatin-encapsulating nanoparticles were statistically indistinguishable from baseline (day 0) control responses. Evoked responses from the uninjected left legs did not differ from the injected right legs (data not shown). These findings suggest that peri-neural administration of lovastatin-encapsulating PLGA nanoparticles in healthy male Lewis rats produces minimal toxicity and trauma to adjacent nerve bundles.
Clinical application of lovastatin-encapsulating PLGA nanoparticles Our group has previously shown that a short-term high-dose course of intraperitoneal administered lovastatin elicits a marked attenuation of EAN in adult male Lewis rats (Sarkey et al. 2007) . Despite these advancements, the clinical application of systemically administered lovastatin for the management of inflammatory autoimmune diseases remains a challenge (Sorensen et al. 2011; Pihl-Jensen et al. 2015) . A more viable option by which to achieve local concentrations of statins capable of mediating pleiotropic effects while minimizing systemic side effects may include the application of nanotechnology. To determine the therapeutic potential of localized administration of lovastatin-encapsulating PLGA nanoparticles in EAN, a bilateral peri-neural injection of empty nanoparticles or lovastatin-encapsulating nanoparticles (25% w/w, 20 mg each) was administered to adult male Lewis rats 5 days prior to disease induction. Rats receiving empty nanoparticles developed a monophasic course of EAN beginning on day 10.8 AE 0.4 and peaking on day 15.9 AE 0.3, post-immunization (Fig. 4a) . In rats receiving lovastatin-encapsulating nanoparticles, a similar monophasic course of EAN developed beginning on day 10.8 AE 0.2 and peaking on day 15.5 AE 0.4, post-immunization. While lovastatin-encapsulating nanoparticles did not alter the course of EAN, the severity of EAN (peak score 3.7 AE 0.2 vs. 1.8 AE 0.1) was significantly attenuated (Fig. 4) . Another independent measure of disease severity is weight loss. EAN rats that had received empty control nanoparticles exhibited weight loss that is characteristically Healthy male Lewis rats received a single peri-neural injection of lovastatin-encapsulating PLGA nanoparticles and 1 week later sera levels of active lovastatin were analyzed by HPLC and found to be below the level of detection. For comparison, levels of activated lovastatin in sera of rats that received lovastatin pro-drug as a single intraperitoneal bolus or by oral gavage, as indicated, are shown. In all cases, levels of the inactive lovastatin pro-drug were below the level of detection. Data shown are the means AE SEM, n = 3-6.
Published 2016. This article is a U.S. Government work and is in the public domain in the USA, J. Neurochem. (2017) 140, 334--346 observed with EAN development, reaching a peak weight loss of 10.6 AE 1.2% body weight on Day 17 (Fig. 4b) . In contrast, EAN rats that received lovastatin-encapsulating nanoparticles exhibited significantly less weight loss (Fig. 4b) . To confirm that lovastatin-encapsulating nanoparticles were most effective when administered locally, in a separate experiment empty control or lovastatin-encapsulating nanoparticles were injected subcutaneously in the thigh rather than perineurally. The course and severity of EAN (Fig. 4c) and degree of weight loss at peak of disease (Fig. 4d ) between these two groups were significantly indistinguishable. The impact of lovastatin-encapsulating nanoparticles on preservation of peripheral nerve function was next assessed using evoked-response electrophysiology. The presence of nanoparticles, whether empty control or lovastatin encapsulated, had no effect on baseline evoked CMAP or calculated NCV (Figs 3c,d and 5 ). At peak of disease, evoked CMAP amplitudes and calculated NCV in EAN rats that received empty control nanoparticles were significantly smaller and slower, respectively, compared to baseline (Fig. 5 ). In contrast, evoked CMAP amplitudes and calculated NCV in EAN rats that received lovastatin-encapsulating nanoparticles were statistically indistinguishable from baseline (Fig. 5) . Toluidine blue-stained transverse sections of sciatic nerves collected from EAN rats that received empty control nanoparticles showed neuropathological evidence of edema, demyelination, axonal damage, and cellular infiltrates (Fig. 6a) . In contrast, stained sections of sciatic nerves collected from EAN rats that received lovastatin-encapsulating nanoparticles had qualitatively less severe neuropathological findings (Fig. 6b) . Sections of sciatic nerves collected from EAN rats that received empty control nanoparticles stained heavily for the presence of perivascular CD4 + T cells (Fig. 6c ) and CD68 + macrophages (Fig. 6e) . In contrast, sections of sciatic nerves collected from lovastatin-encapsulating nanoparticles had qualitatively less CD4 + (Fig. 6d ) and CD68 + (Fig. 6e ) perivascular infiltrates. Collectively, these findings support a protective effect of locally administered lovastatin-encapsulating nanoparticles against EAN-associated deficits in peripheral nerve function.
Discussion
In this study, a well-established biodegradable nanotechnology-based drug delivery approach was implemented as a new and innovative strategy by which to locally administer therapeutic compounds exhibiting low bioavailability, high systemic toxicity, and/or poor water solubility for the management of systemic inflammatory peripheral nerve disorders. Here, we report that a one-time localized perineural application of lovastatin-encapsulating PLGA nanoparticles significantly attenuates the clinical development of systemic experimental autoimmune neuritis (EAN), a well-established animal model of AIDP/GBS.
PLGA nanoparticles are ideal biodegradable candidates with which to efficiently encapsulate hydrophobic compounds for controlled and sustained release (Astete and Kulkarni and Kompella 2014) . Previous studies from our laboratory have shown that a short-term high-dose course of intraperitoneally administered statins markedly restricts the transendothelial trafficking of autoreactive leukocytes into peripheral nerves of adult male Lewis rats and safely attenuates the development and progression of EAN. Despite these advancements, the clinical application of systemically administered statins for the management of inflammatory disorders remains controversial as a result of disappointingly inconclusive phase trials.
To resolve these limitations, a previously described oil-inwater single emulsion technique was used to encapsulate variable amounts of lovastatin pro-drug into PLGA nanoparticles having either a 50 : 50 or 85 : 15 lactide : glycolide ratio. In agreement with previous studies (Zaghloul et al. 2005) , nanoparticles composed of 85 : 15 lactide : glycolide yielded slightly higher encapsulation efficiencies compared to those having a 50 : 50 ratio, possibly because of a higher hydrophobicity of the 85 : 15 co-polymer. While higher drug-loading conditions have been reported to yield largersize nanoparticles (McAlvin et al. 2013) , PLGA nanoparticles prepared using the oil-in-water single emulsion technique exhibited an average particle size of 260.0 AE 14.4 nm that was not influenced by polymer composition or drugloading efficiency, consistent with earlier reported findings (Panyam et al. 2004; Astete and Sabliov 2006) .
Polymer composition was found to influence release of lovastatin from encapsulated PLGA nanoparticles. Previous studies have shown that PLGA nanoparticles prepared with a lower lactide content hydrolyze more quickly, thus releasing encapsulated compounds on a shorter time scale (Wischke and Schwendeman 2008) . In our hands, however, at a drug load burden of 6.25%, lovastatin-encapsulating nanoparticles prepared with an 85 : 15 lactide : glycolide ratio released lovastatin into the dialysate at a near linear rate of~5% per day. Nanoparticles prepared with a lower (50 : 50) content of lactide, by comparison, exhibited a bi-phasic release profile approximating~2.5% per day over the first 10 days and a subsequent rate of release of nearly 5% per day. Both co-polymers preparations of lovastatin-encapsulating PLGA nanoparticles (50 : 50; 85 : 15) reached 85% cumulative release by days 20.3 AE 2.9 and 19.0 AE 1.8, respectively. Increasing the drug load to 25% measurably enhanced the rate of lovastatin release from 85 : 15 PLGA nanoparticles tõ 6% per day. When administered orally or by intraperitoneal injection, lovastatin pro-drug is rapidly activated to the open-ring hydroxy acid isoform by CYP3A4 cytochrome P450 (Romana et al. 2014) . While cytochrome P450 is highly expressed in the liver, it is also expressed in other tissues including lung, small intestine, kidney, esophagus, and olfactory mucosa (Ding and Kaminsky 2003; Yang and Hwang 2006; McLaughlin et al. 2010) . PLGA nanoparticles prepared using the oil-in-water single emulsion technique were found to encapsulate and retain lovastatin in its prodrug lactone confirmation. Upon release of the encapsulated pro-drug, however, lovastatin is converted into the active hydroxy acid isoform, consistent with previous reports of non-enzymatic conversion of the lactone pro-drug within an aqueous environment (Shen et al. 1996; Ye et al. 2000) .
By limiting the availability of isoprenoid metabolic intermediates, we have previously shown that statins elicit a marked compensatory increase in constitutive RhoA and inducible RhoB mRNA expression (Stubbs and Von Zee 2012) . PNMEC cultures responded robustly to lovastatin-encapsulating PLGA nanoparticles by significantly increasing Rho GTPase mRNA content in a manner similar to that seen following the addition of chemically activated lovastatin hydroxy acid. Given their dimensions (~260 nm), it is unlikely that cultured cells physically respond to the PLGA nanoparticles themselves. We speculate that the observed effects elicited by the lovastatin-encapsulating nanoparticles are most likely as a result of release of the pro-drug into the culture media with subsequent nonenzymatic, or metabolic, conversion into its hydroxy acid active isoform.
When evaluated in vivo, we found that unilateral perineural administration of lovastatin-encapsulating PLGA nanoparticles to na€ ıve healthy rats produced a qualitatively similar increase in ipsilateral sciatic nerve and muscle tissue Rho GTPase mRNA content. By comparison, perineural co-administration of empty nanoparticles within the contralateral limb had no effect on adjacent sciatic nerve or muscle tissue Rho GTPase mRNA expression, supporting a localized, rather than systemic, effect of the lovastatin-encapsulating nanoparticles. The content of lovastatin pro-drug, or activated isomer, in the serum of rats receiving peri-neural lovastatin-encapsulating nanoparticles was below the level of detection by HPLC. Perineural administered lovastatin-encapsulating nanoparticles remained localized as a globular deposit adjacent to the nerve fiber bundle, presumably optimizing their functional efficacy while minimizing previously encountered systemic complications. Of particular clinical relevance, in vivo perineural administration of lovastatin-encapsulating nanoparticles did not significantly alter peripheral nerve-evoked CMAP amplitudes or conduction velocities in healthy animals.
Previous studies have shown that a short-term high-dose regimen of intraperitoneally administered lovastatin significantly attenuates the progression of EAN in adult male Lewis rats (Sarkey et al. 2007) , possibly by limiting chemokine (C-C motif) ligand 2-mediated transendothelial migration of autoreactive leukocytes into peripheral nerve (Langert et al. 2013b) . Given that lovastatin-encapsulating nanoparticles administered adjacent to healthy peripheral nerve locally disrupted Rho GTPase signaling without adversely affecting peripheral nerve function, we evaluated the ability of these nanoparticles to protect against the development and progression of EAN. Rats that received bilateral peri-neural administration of lovastatin-encapsulating nanoparticles developed a significantly less severe course of EAN compared to rats receiving empty nanoparticles. Peripheral nerve function studies supported a protective effect of lovastatin-encapsulating nanoparticles against the development of EAN.
The mechanism by which these nanoparticles exert their protective effect is suggested by a reduced presence of CD68 + macrophage and CD4 + T-cell infiltrates in sciatic nerves compared to nerves harvested from empty nanoparticle-treated EAN rats. It is well established that proinflammatory CD8 + and CD4 + T-cell subsets play a penultimate role in the development of both EAN and AIDP/GBS (Zhang et al. 2013; Calik et al. 2015) . Similarly, depending on disease stage, macrophage subsets (M1, M2) may initiate induction of, or facilitate recovery from, EAN Shin et al. 2013) . It remains to be determined whether lovastatin-encapsulating nanoparticles elicit protection against EAN by selectively altering the distribution of infiltrating macrophage (M1, M2) and/or CD8 + and CD4 + T cell (Th1, Th2, Th17, Tregs) subsets during the induction or effector phase of this disease.
In this study, we report the preparation and characterization of PLGA nanoparticles-encapsulating lovastatin. We demonstrate in vitro and in vivo that lovastatin-encapsulating nanoparticles afford meaningful protection against the clinical development of EAN, possibly by a mechanism that involves disruption of autoreactive leukocyte trafficking at the bloodnerve barrier. Limitations of this study include (i) prophylactic proof of concept and (ii) localized administration of nanoparticles, which do not address therapeutic relevance. Systemic administration of functionalized nanoparticles engineered to recognize and adhere to the activated endoneurial endothelium offers a promising approach by which to address therapeutic relevance for the management of advanced, more extensively involved, inflammatory neuropathies. This study provides the first proof-of-concept approach for the application of a nanoparticle-based local drug delivery platform for the management of inflammatory demyelinating diseases, including AIDP/GBS.
